Recently reported by BioSpace, new research highlights the expanding benefits of GLP-1 medications beyond weight loss and diabetes management. These drugs, including Novo Nordisk’s Wegovy and Lilly’s Zepbound, are now being recognized for their impact on heart health.
The FDA recently approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in patients with cardiovascular disease and obesity or overweight. The decision was based on a study showing a 20% reduction in major heart events among patients using the medication. Another study found that even those without severe heart disease had a 15% to 20% lower risk of major cardiac events after three years on a GLP-1 drug.
While weight loss plays a role, researchers believe these medications may also directly improve blood vessel function and reduce inflammation. For individuals with peripheral artery disease (PAD), maintaining proper blood flow is important for reducing the risk of heart attack and stroke.
At USA Vascular Centers, we emphasize the importance of early screening, lifestyle changes, and innovative treatment options to protect vascular health. If you have symptoms of PAD, such as leg pain or numbness, schedule a consultation today and take control of your vascular health.
To learn more about how GLP-1 medications can improve cardiovascular health, read the full story here.
